JPM 2026 Insights by Cyagen: AI Transformation, Globalization 2.0, and Emerging Innovations in Core Modalities from Next-Gen ADCs to Degrader-Antibody Conjugates (DACs)

This white paper aims to systematically analyze the current status and trends of the global and Chinese BsAb markets, explore key technological bottlenecks in depth, and introduce how Cyagen Biosciences leverages its HUGO-Ab™ series of fully human antibody mice.

This brochure details Cyagen's strong technological capabilities and proprietary TurboKnockout® ES targeting technology to generate the next-generation HUGO-Ab™ Humanized Antibody Mouse. These mice carry a complete set of human immunoglobulin genes and can produce fully human antibodies with high affinity and low immunogenicity in vivo.

This poster highlights Cyagen’s Human Genomic Ortholog (HUGO) mouse models, which enable detailed studies of human-specific biological processes and disease mechanisms. These models, including fully humanized genes such as hMAPT (with or without P301L/P301S mutations) and hMECP2-T158M, faithfully recapitulate key features of neurological disorders like Alzheimer’s disease, frontotemporal lobar degeneration, and Rett syndrome.

This brochure details Cyagen's comprehensive, end-to-end neuropharmacology CRO solutions. We provide the global neuroscience community with a full suite of services, from developing a wide range of neurological disease models to precise drug injection and thorough pharmacological analysis.

This pamphlet introduces Cyagen’s mouse models for human immune system reconstruction, featuring PBMC and HSC-based strategies validated in oncology, immunology, and infectious disease research.